HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use NYVEPRIA safely and effectively. See full prescribing information for NYVEPRIA. NYVEPRIA™ (pegfilgrastim-apgf) injection, for subcutaneous use Initial U.S. Approval: 2020 NYVEPRIA (pegfilgrastim-apgf) is biosimilar* to NEULASTA (pegfilgrastim) (1) RECENT MAJOR CHANGESINDICATIONS AND USAGENYVEPRIA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1) Limitations of Use NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. (1) DOSAGE AND ADMINISTRATIONPatients with cancer receiving myelosuppressive chemotherapy DOSAGE FORMS AND STRENGTHSInjection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only. (3) CONTRAINDICATIONSPatients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim products or filgrastim products. (4) WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common adverse reactions (≥5% difference in incidence compared to placebo) are bone pain and pain in extremity. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. *Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 3/2023 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
NYVEPRIA Highlights (pegfilgrastim-apgf)
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.